Neoadjuvant cisplatin-based chemotherapy (NACC) is a standard of care for muscle-invasive urothelial bladder carcinoma (MIBC), and complete responses at cystectomy are associated with improved overall survival. Somatic mutations in ERCC2, a member of the nucleotide excision repair pathway, correlated with pathologic response in a clinical discovery cohort and conferred cisplatin sensitivity in preclinical systems.1 Herein, we investigate this association in an independent validation patient cohort.
Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-1096. doi:10.1001/jamaoncol.2016.1056